Showing 3631-3640 of 6951 results for "".
- Zerigo Health Appoints Lisa Rometty as CEOhttps://practicaldermatology.com/news/zerigo-health-appoints-lisa-rometty-as-chief-executive-officer/2461910/Lisa Rometty is the new Chief Executive Officer at Zerigo Health. Ms. Rometty joins Zerigo after serving as Presi
- Skin Cancer-related Mutations Higher in the UK Than Singaporehttps://practicaldermatology.com/news/skin-cancer-related-mutations-higher-in-the-uk-than-singapore/2461909/People in the UK have facial skin that is far more DNA damaged from the sun than people in Singapore, explaining the far higher risk of developing basal and squamous cell carcinomas in the UK, new research suggests. When researchers from the Wellcome Sanger Institute and their collabora
- Golfers Face Higher Risk for Skin Cancerhttps://practicaldermatology.com/news/golfers-face-higher-risk-for-skin-cancer/2461902/New research from the University of South Australia shows that golfers have a higher risk of skin cancer when compared to the general population. Fully 27% of golfers – or one in four – had been diagnosed with skin cancer, as compared with 7% of the gener
- Research Closes in on the Genetic Factors Underlying HS Riskhttps://practicaldermatology.com/news/research-closes-in-on-the-genetic-factors-underlying-hs-risk/2461893/Researchers have identified genetic locations for increased risk of hidradenitis suppurativa (HS). “This discovery is highly relevant because these changes may effect nearby genes in a way that leads to improper development of hair follicles and predispose them to the rupture,&rdq
- Taylor Harris Named New CEO at Cuterahttps://practicaldermatology.com/news/taylor-harris-named-new-ceo-at-cutera/2461892/Taylor Harris has been appointed Chief Executive Officer for Cutera, Inc., effective August 7, 2023. Mr. Harris will succeed Sheila Hopkins, who has been serving as Interim Chief Executive Officer since April 2023. Mr. Harris and Ms. Hopkins will both continue serving as memb
- Enspectra Health Awarded NIH Grant to Advance Predictive Algorithms for AKshttps://practicaldermatology.com/news/enspectra-health-awarded-nih-grant-to-advance-predictive-algorithms-for-aks/2461874/Enspectra Health scored $2M in grant funding from the National Cancer Institute (NCI) to support research for developing deep learning algorithms to predict which actinic keratosis (AK) lesions, are likely to progress to squamous cell carcinoma (SCC). Enspectra's technolog
- Hoth Therapeutics Receives Protocol Approval for HT-001https://practicaldermatology.com/news/hoth-therapeutics-receives-protocol-approval-for-ht-001/2461873/Hoth Therapeutics, Inc. received approval from the Food & Drug Administration (FDA) for a protocol change in its Phase 2a clinical trial of HT-001. Participants will apply HT-001 Gel once per day for six weeks, during which the effect on treating acneiform rash and other skin
- EMA to Review UCB’s Bimekizumab for HShttps://practicaldermatology.com/news/ema-to-review-ucbs-bimekizumab-for-hs/2461869/The European Medicines Agency (EMA) will reviww UCB’s marketing authorization application for bimekizumab for the treatment of adults with moderate to severe hidradenitis suppurativa (HS). Bimekizumab is an IL-17A and IL-17F inhibitor. The safety and efficacy of bim
- Revian Red Hair Growth System Takes on CCCA in Second Studyhttps://practicaldermatology.com/news/revian-red-hair-growth-system-takes-on-ccca-in-second-study/2461864/Revian Red Hair Growth System is planning a second study to build on previous trial results as an effective treatment for Central Centrifugal Cicatricial Alopecia (CCCA). The Revian Red Hair Growth System is a US Foof and Drug Administration- cleared, lightweight wirel
- Soligenix, Inc.’s SGX302 (Synthetic Hypericin) Demonstrates “Clear Biological Signal” in Phase 2a PsO Studyhttps://practicaldermatology.com/news/sgx302-synthetic-hypericin-demonstrates-clear-biological-signal-in-phase-2a-pso-study/2461854/Soligenix, Inc.’s SGX302 (synthetic hypericin) showed a clear